Huxley Medical

Huxley Medical develops SANSA, an FDA-cleared home sleep apnea testing platform that integrates cardiac monitoring capabilities. The company's flagship product is a single wireless patch that captures nine channels of physiological data, including ECG, enabling healthcare providers to diagnose sleep apnea and detect cardiac arrhythmias like atrial fibrillation from a patient's home.

The SANSA system combines direct-to-patient device delivery, cellular data upload without smartphone apps, and AI-powered auto-scoring through the cloud-based Huxley HUB platform. The device has been validated against gold-standard polysomnography in what the company describes as the largest multi-site clinical trial of its kind. Recent FDA clearances include central sleep apnea detection and diagnostic ECG capabilities, positioning SANSA as the first solution to systematically detect arrhythmias during home sleep testing.

Huxley Medical focuses on streamlining workflow efficiency for sleep medicine practices and cardiology departments by eliminating lengthy referral processes and reducing testing backlogs through scalable, app-free remote monitoring technology.

Healthcare organizations should consider Huxley Medical when seeking to eliminate sleep testing backlogs while simultaneously screening for cardiac arrhythmias. The platform excels in settings where streamlined patient workflow and operational efficiency are priorities, particularly for practices lacking resources for traditional polysomnography or managing patients with suspected comorbid cardiac conditions.

Expect a turnkey solution with device fulfillment, 24/7 patient support, and cloud-based scoring that reduces clinic staff burden. The single-patch, app-free design minimizes patient calls and technical troubleshooting compared to multi-device home sleep testing systems.

Huxley Medical operates exclusively in healthcare, specifically serving sleep medicine and cardiology specialties. The company has secured multiple FDA clearances for diagnostic use, including 510(k) clearances for sleep apnea testing, central sleep apnea detection, and diagnostic ECG. The HIPAA-compliant platform addresses the intersection of sleep disorders and cardiac arrhythmias, conditions with significant clinical overlap in patient populations.

The company's clinical validation through multi-site trials and presentations at major medical conferences (SLEEP 2025, Heart Rhythm Society) demonstrates commitment to evidence-based healthcare applications. Their Medical Director of Sleep Medicine appointment and peer-reviewed publications further establish clinical credibility within specialized healthcare verticals.

Sleep medicine practices and cardiology departments seeking to increase diagnostic capacity without expanding physical infrastructure. Health systems managing high volumes of suspected sleep apnea patients with cardiac comorbidities. Organizations prioritizing patient convenience through home-based testing and seeking validated alternatives to in-lab polysomnography with integrated cardiac monitoring capabilities.